Brummer & Partners, which manages about $6 billion, set up the Frontier Fund in July to invest in Bangladeshi stocks and private equity. It plans to grow the fund to about $500 million in the next five years, said Khalid Quadir, CEO of the firm's unit in Dhaka. Bangladesh may join the ranks of the fastest-growing economies in the region as it benefits from its geographical proximity to India and China. The nation of 150 million people, equivalent to about half of the population of the U.S., offers a ``huge untapped cheap labor force,'' Quadir, 43, said.
Via Bangladesh Blogger
The number of properties repossessed by mortgage lenders rose by 12% to 11,300 in the UK, the Council of Mortgage Lenders has said. The CML reports that 1.44% of mortgages were at least three months in arrears as at the end of September 2008. This was up from 1.33% at the end of June. The number of cases in arrears at the end of September was 168,000, 8% higher than June.
BBC News: Repossession of homes up by 12%

A man reacts, while watching a display screen at the Bombay Stock Exchange (BSE) building in Mumbai. The BSE's benchmark Sensex fell as much as 4.1% percent.
> AP-Image
Founded by Kiran Mazumdar-Shaw, India's richest self-made businesswoman, Biocon is India's biotechnology pioneer. Its founder was named as one of Fortune magazine's 50 Most Powerful Women in 2007 and was instrumental in forging India's biotechnology industry. She set up Biocon in 1978 and has developed it into a global biopharmaceutical player with highly developed research and development facilities focusing on cancer and diabetes treatments.
> Quiz India's mother of invention
Biocon has rapidly developed a robust drug pipeline, led by monoclonal antibodies and other molecules at exciting stages in the bio-pharmaceutical value chain.
Over the years, Biocon has evolved from an enzyme-manufacturing company into a fully integrated bio-pharmaceutical enterprise.
Leveraging India’s globally competitive cost base and exceptional scientific people resource, they are advancing their in-house R&D programs, while also providing custom and clinical research services to international pharmaceutical and biotechnology majors through their subsidiary companies, Syngene and Clinigene.
Biocon is India's first biotechnology company, established in 1978.
It is the first Indian firm to receive US funding for proprietary technologies.
Biocon is the first Indian company to be approved by US FDA for the manufacture of lovastatin, a cholesterol-lowering molecule.
Biocon created a huge stock market buzz in March 2004 with its successful IPO. Day 1 closed with a market value of $1.11 billion.
Subsidiary Companies:
Syngene is a custom research organisation offering synthetic chemistry and molecular biology services for early stage drug discovery and development.
Clinigene is a clinical research organisation offering Phase I-IV clinical trials and studies for novel/generic molecules to international pharmaceutical majors.
Biocon Biopharmaceuticals Private Limited (BBPL) is a joint venture with CIMAB to develop and market a range of monoclonal antibodies and cancer vaccines.
While Barack Obama may have his hands full, the rest of us need to be thinking about our plates. Interestingly, one of the ways to start doing this would be to stay right where you are -- in front of your computer. The Internet has emerged as an incredible tool for planning. The Eat Well Guide is hoping to help people make good decisions about what they eat and how.
Via AlertNet
Cheap money! Come and get it, bankers. Uncle Sam is opening the vaults at the Treasury. Oh, there will be strings attached, of course. And if your bank desperately needs the money, the government won't give it to you.
Some banks taking the money are salivating at the chance to grow their loan portfolios and perhaps gobble up a few weaklings among area banks. The Treasury is offering to buy preferred stock in banks. The money counts as capital, which means that a healthy bank could, in theory, make new loans in an amount 10 times the amount of the Treasury's investment. The government will also take warrants allowing it to take stock in the company, diluting current shareholders.
>> There would be limits on golden parachutes.
More worrisome: The feds say they may add additional requirements later, and there are rumblings in Congress about lending requirements and restrictions.
Via stltoday.com/ssave
Pakistan's new agreement with the International Monetary Fund over a $7.6 billion loan may lead to more help from other donors.
But the IMF's package falls well short of the $10 billion to $15 billion that Pakistani officials have said they need over the next two years to fix the economy.
Some of that shortfall will be made up by loans from the World Bank and Asian Development Bank. The IMF will deliver $4 billion – the amount Pakistan says it needs immediately to avoid defaulting – this year, with the rest to be disbursed in 2009, said Shaukat Tarin, an economic adviser to Pakistan's prime minister.
Via WSJ